Announcements
Projects
Orgs
Project
Articles 3
Votes 0
Jnj.com

Authors 1

Tamekia Reece
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE® (lazertinib) - Johnson & Johnson
3d
Johnson & Johnson Marks New Era as Global Healthcare Company with Updated Visual Identity - Johnson & Johnson
>2y
"As Black Men, We Keep Things Close to the Hip": 5 Questions for a Urologist About Prostate Cancer - Johnson & Johnson
almost3y